Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures
Johnson Fistel, PLLP is investigating Simulations Plus, Inc. (NASDAQ: SLP) following significant financial setbacks, including a revenue guidance cut and public accounting firm dismissal. The investigation comes after Simulations Plus reduced its fiscal 2025 revenue guidance due to customer budget reductions and project delays, leading to a substantial decline in share price. Further concerns arose from a large net loss, a non-cash impairment charge, and the termination of their independent registered public accounting firm, which identified issues with segment reporting and internal controls.
Shareholder Alert: Ademi LLP investigates whether Simulations Plus, Inc. is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Simulations Plus (NASDAQ: SLP) regarding potential breaches of fiduciary duty due to its recent transaction with Altaris. Shareholders are set to receive $18.50 per share in an all-cash deal valued at approximately $375 million, with insiders reportedly receiving substantial benefits. The law firm is examining if the board of directors is fulfilling its duties to all shareholders and if the transaction agreement unfairly limits competing bids.
Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel
Johnson Fistel, PLLP is investigating potential securities law violations concerning Simulations Plus (SLP) after the company restated revenue guidance and disclosed a significant net loss and impairment charge. The investigation focuses on whether Simulations Plus made false or misleading statements regarding its financial outlook and internal controls. Investors who suffered losses after the stock declined following these announcements are encouraged to contact Johnson Fistel to explore their legal rights.
SLP (NASDAQ: SLP) insiders report two 15,000-share 10b5-1 sales
A recent SEC Form 144 filing indicates that Virginia Evans Woltosz and Walter S. Woltosz, identified as sellers, made two planned sales of 15,000 shares each of SLP (Simulations Plus, Inc.) common stock under a 10b5-1 plan. These transactions occurred on May 4, 2026, for $226,899 and on June 1, 2026, for $261,394.50, totaling 30,000 shares and approximately $488,293.50. Such filings are routine compliance disclosures for insider sales through prearranged trading plans, confirming transactions previously established to avoid accusations of trading on non-public information.
Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel
Johnson Fistel, PLLP is investigating potential securities law violations by Simulations Plus, Inc. (NASDAQ: SLP) following significant stock declines. The investigation focuses on whether the company made false or misleading statements regarding its financial outlook, reporting practices, and internal controls, particularly after revising its fiscal 2025 revenue guidance downward and the subsequent dismissal of its independent auditor amid disagreements over financial reporting matters. Investors who suffered losses are encouraged to contact Johnson Fistel to explore their legal rights.
SLP Investors Have Opportunity to Join Simulations Plus, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Simulations Plus, Inc. (NASDAQ: SLP) for potential securities law violations, focusing on whether the company issued false or misleading statements. Shareholders who have suffered a loss are encouraged to contact the firm to discuss their rights and participate in the fraud investigation.
Simulations Plus, Inc. (SLP) Stock Price Today & Analysis
This article provides an analysis of Simulations Plus, Inc. (SLP) stock, including its fundamental financials, corporate actions, and valuation metrics. It details how to buy SLP stock on the Gotrade app, explains the minimum investment, and clarifies that SLP does not currently pay dividends as it is a growth stock. The company is primarily engaged in developing software for pharmaceutical research and provides consulting services, generating most of its revenue from the software segment.
Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel
Johnson Fistel, PLLP is investigating potential securities law violations by Simulations Plus, Inc. (NASDAQ: SLP) following significant stock declines. The investigation focuses on whether the company made false or misleading statements regarding its financial outlook, reporting practices, internal controls, and related accounting matters, particularly after revised revenue guidance and the dismissal of their independent auditor due to unresolved issues. Investors who suffered losses are encouraged to contact Johnson Fistel to explore their legal rights.
Simulations Plus, Inc.(NasdaqGS: SLP) added to Russell Microcap Value Benchmark Index
Simulations Plus, Inc. (NasdaqGS: SLP), a company specializing in model-informed and AI-accelerated drug development, has been added to the Russell Microcap Value Benchmark Index. This inclusion highlights the company's market presence and its focus on providing software and consulting solutions for pharmaceutical research and development. The news comes amid other recent announcements, including analyst downgrades and a definitive agreement for Altaris, LLC to acquire the company.
Price to earnings forward of Simulations Plus, Inc. – GETTEX:SD3
This page provides financial data, specifically the price-to-earnings forward, for Simulations Plus, Inc. (SD3) listed on Gettex. The content is presented within the TradingView platform, offering an overview of financial metrics for the company.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Simulations Plus, Inc. (SLP) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Simulations Plus, Inc. (NASDAQ:SLP) after the company's stock dropped significantly following a weaker-than-expected third-quarter 2025 earnings report. Simulations Plus reported sales of $20.4 million, missing consensus estimates and leading to a 25.75% stock price decline on July 15, 2025. The firm is encouraging investors affected by this drop to connect with them for the investigation.
Simulations Plus, Inc. Actuals & Estimates (NASDAQ:SLP)
This article provides an overview of Simulations Plus, Inc. (NASDAQ: SLP) stock performance, financial data, and analyst estimates. It includes current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings dates. The article also answers frequently asked questions about investing in SLP stock.
SLP Forecast — Price Target — Prediction for 2027
The article provides a forecast for Simulations Plus, Inc. (SLP) stock, including analyst price targets and ratings. It also offers key financial metrics, historical price performance, and answers frequently asked questions about the company's stock, such as current price, market capitalization, earnings, and revenue.
Simulations Plus Advances Agentic Drug Development with NVIDIA BioNeMo Agent Toolkit
Simulations Plus announced its collaboration with NVIDIA to integrate the NVIDIA BioNeMo Agent Toolkit into its Composer platform, aiming to advance agentic drug development. This initiative will leverage AI agents, scientific literature, and validated computational engines to accelerate model-informed drug development, with an initial focus on enhancing scientific reasoning with trusted evidence and accelerating quantitative systems pharmacology. The goal is to make drug development more efficient, reproducible, and grounded in validated science.
Simulations Plus Advances Agentic Drug Development with NVIDIA BioNeMo Agent Toolkit
Simulations Plus, Inc. announced its collaboration with NVIDIA to integrate the NVIDIA BioNeMo Agent Toolkit into its Composer platform, aiming to accelerate model-informed drug development. This initiative focuses on using AI agents to ground scientific reasoning in trusted evidence and scale quantitative systems pharmacology, leveraging NVIDIA's AI reasoning and computational power with Simulations Plus's validated scientific engines. The goal is to enhance efficiency in drug development while maintaining scientific rigor and reproducibility.
Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel
Johnson Fistel, PLLP is investigating potential securities law violations by Simulations Plus, Inc. (NASDAQ: SLP) after the company significantly lowered its fiscal 2025 revenue guidance and disclosed a large net loss including an impairment charge. The investigation was prompted by two significant stock declines following these announcements and the subsequent dismissal of their accounting firm, Grant Thornton LLP, which noted unresolved issues with Simulations Plus's reporting practices. Investors who suffered losses after purchasing SLP securities are encouraged to contact Johnson Fistel to explore their legal rights.
Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel
Johnson Fistel, PLLP is investigating potential securities law violations concerning Simulations Plus, Inc. (NASDAQ: SLP) after the company experienced significant stock declines following reduced revenue guidance and the dismissal of its independent auditor. The investigation centers on whether Simulations Plus made misleading statements or failed to disclose material information regarding its financial outlook, reporting practices, internal controls, and accounting matters. Investors who suffered losses are encouraged to contact Johnson Fistel to explore their legal rights.
Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel
Johnson Fistel, PLLP is investigating potential securities law violations involving Simulations Plus, Inc. (NASDAQ: SLP) after the company reduced its full-year fiscal 2025 revenue guidance and disclosed a significant net loss and impairment charge. The investigation was prompted by stock declines following these announcements, which also included the dismissal of Simulations Plus's independent registered public accounting firm, Grant Thornton LLP, over unresolved issues regarding financial reporting and internal controls. Investors who suffered losses are encouraged to contact Johnson Fistel to join the investigation.
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Simulations Plus, Inc. (NASDAQ: SLP)
Monteverde & Associates PC, a class action firm, announced an investigation into Simulations Plus, Inc. (NASDAQ: SLP) following its proposed sale to affiliates of Altaris, LLC for $18.50 per share in cash. The firm, led by attorney Juan Monteverde, is assessing whether the proposed transaction offers a fair value to Simulations Plus shareholders. Shareholders are encouraged to seek more information regarding the fairness of the deal without cost or obligation.
Simulations Plus, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – SLP
The DJS Law Group has announced an investigation into Simulations Plus, Inc. (NASDAQ: SLP) regarding potential violations of securities laws. The investigation will focus on whether the company made misleading statements or failed to disclose material information to investors. Shareholders who have incurred losses are encouraged to contact the DJS Law Group to discuss their rights and participation in the investigation.
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Simulations Plus, Inc. (NASDAQ: SLP)
Monteverde & Associates PC, an M&A class action firm, has initiated an investigation into Simulations Plus, Inc. (NASDAQ: SLP) following its proposed sale to affiliates of Altaris, LLC for $18.50 per share in cash. The firm is evaluating whether this per-share price represents a fair deal for Simulations Plus shareholders. Shareholders are encouraged to contact the firm for more information regarding the investigation.
Simulations Plus Agrees to Be Acquired by Altaris Affiliate for $18.50 Per Share in Cash
Simulations Plus has entered into an agreement to be acquired by an Altaris affiliate for $18.50 per share in cash, a deal that will take the company private. The transaction is contingent on shareholder and regulatory approvals, and the founders, Walter and Virginia Woltosz, who own approximately 16% of shares, have agreed to vote in favor of the merger. Upon completion, Simulations Plus will become a wholly owned subsidiary of the Altaris affiliate and will be delisted from Nasdaq.
Simulations Plus (NASDAQ: SLP) agrees to $18.50-per-share all-cash sale
Simulations Plus (NASDAQ: SLP) has entered into a definitive agreement to be acquired by an affiliate of Altaris, LLC for $18.50 per share in an all-cash transaction. The deal requires approval from a majority of Simulations Plus shareholders and regulatory clearances, but is not subject to a financing condition. Major shareholders Walter and Virginia Woltosz, holding approximately 16% of the company, have agreed to vote in favor of the merger.
Simulations Plus To Be Acquired By Altaris For Approximately $375 Million
Simulations Plus has announced its acquisition by affiliates of Altaris for approximately $375 million in an all-cash transaction, delivering stockholders $18.50 per share. Altaris plans to merge Simulations Plus with its existing portfolio company, Chemical Computing Group, to create an integrated platform for the life sciences industry. The deal, unanimously approved by Simulations Plus's Board, is anticipated to close in Q4 2026, making Simulations Plus a privately held subsidiary.
Altaris to acquire Simulations Plus in $375m all-cash deal
Altaris is set to acquire Simulations Plus (SLP) in an all-cash deal worth approximately $375 million. Simulations Plus shareholders will receive $18.50 per share, a 26% premium. Altaris plans to combine Simulations Plus with its portfolio company, Chemical Computing Group (CCG), to create a more comprehensive biosimulation platform for drug discovery and development.
Altaris to acquire Simulations Plus in $375m all-cash deal
Altaris is set to acquire Simulations Plus in an all-cash deal worth approximately $375 million, with shareholders receiving $18.50 per share. The acquisition, expected to close in Q4 2026, will see Simulations Plus combine with Altaris's portfolio company Chemical Computing Group to create a comprehensive biosimulation platform. Simulations Plus will become a privately held subsidiary of Altaris, remaining in North Carolina, and its shares will be delisted from Nasdaq.
Simulations Plus agrees to $18.50 per share Altaris buyout
Simulations Plus, Inc. has announced a definitive agreement to be acquired by affiliates of Altaris, LLC for $18.50 per share in an all-cash transaction, representing a 26% premium to its 60-day volume-weighted average price. Altaris plans to combine Simulations Plus with its existing portfolio company, Chemical Computing Group, upon closing in the fourth quarter of 2026. The acquisition was unanimously approved by Simulations Plus's Board of Directors and is supported by cofounder Dr. Walter Woltosz.
Simulations Plus (SLP) accepts $18.50 per share all-cash buyout from Altaris
Simulations Plus, Inc. has agreed to an all-cash acquisition by Altaris affiliates for approximately $375 million, with stockholders receiving $18.50 per share, representing a 26% premium to the 60-day volume-weighted average price. The deal is expected to close in Q4 2026, after which Simulations Plus will become a private subsidiary of Altaris and cease trading on Nasdaq, and is anticipated to combine with Altaris's portfolio company, Chemical Computing Group. The transaction has been unanimously approved by the board, and co-founder Dr. Walter Woltosz has agreed to vote his shares in favor.
Simulations Plus to Be Acquired by Altaris For Approximately $375 Million
Simulations Plus, Inc. announced its definitive agreement to be acquired by Altaris, LLC for approximately $375 million in an all-cash transaction. Stockholders will receive $18.50 per share, representing a 26% premium. This acquisition is expected to strengthen Simulations Plus by combining it with Altaris' existing portfolio company, Chemical Computing Group, to accelerate growth and innovation in AI-driven drug development platforms.
SLP Investors Have Opportunity to Join Simulations Plus, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm has announced an investigation into Simulations Plus, Inc. (NASDAQ: SLP) on behalf of investors. The firm is looking into whether the company made false or misleading statements and failed to disclose critical information, in violation of securities laws. Shareholders who have incurred losses are encouraged to contact the Schall Law Firm to discuss their rights.
Biotech Pharma Client Simulations Plus To Be Acquired for Approximately $375 Million
Simulations Plus (SLP), a leading biopharma innovation company, is set to be acquired by investment firm Altaris LLC for approximately $375 million in cash. Shareholders will receive $18.50 per share, reflecting a 26% premium. Procopio attorneys, led by Managing Partner Dennis Doucette, represented Simulations Plus in this transaction, which is expected to close in late 2026.
Simulations Plus (SLP) president logs 1,050-share 10b5-1 sale and option exercise
Jill Fiedler-Kelly, President of Services Solutions at Simulations Plus (SLP), reported exercising 1,050 employee stock options at $10.05 per share and subsequently selling the same number of shares on the open market at $16.51 per share. This transaction was pre-arranged under a Rule 10b5-1 trading plan. After the sale, Fiedler-Kelly directly holds 77,817 shares of Simulations Plus common stock and 7,350 outstanding stock options.
Shareholder Alert: Ademi LLP investigates whether Simulations Plus, Inc. is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Simulations Plus (NASDAQ: SLP) for potential breaches of fiduciary duty due to its recently announced all-cash transaction with Altaris, valued at approximately $375 million ($18.50 per share). The investigation focuses on whether the board fulfilled its duties to shareholders, especially considering the benefits insiders will receive and a significant penalty if Simulations Plus accepts a competing bid. The law firm is inviting shareholders to join their investigation.
Shareholder Alert: Ademi LLP investigates whether Simulations Plus, Inc. is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Simulations Plus (NASDAQ: SLP) regarding potential breaches of fiduciary duty related to its announced all-cash acquisition by Altaris for $18.50 per share, valuing the transaction at approximately $375 million. The investigation focuses on whether the deal provides a fair price for public shareholders, especially given that Simulations Plus insiders will benefit substantially from change-of-control arrangements and the transaction agreement includes a significant penalty for competing bids. Ademi LLP encourages shareholders to contact them to learn more about the investigation.
Altaris scoops up AI drug development outfit for $375M
Healthcare private equity firm Altaris is acquiring Simulations Plus, an AI-accelerated drug development company, for $375 million in cash. This acquisition aims to bolster Altaris's presence in AI-based drug discovery and development. Simulations Plus will be combined with Altaris's existing portfolio company, Chemical Computing Group, providing a synergistic platform for pharmaceutical and biotech industries.
Latham & Watkins Advises on Altaris Acquisition of Simulations Plus for Approximately US$375 Million
Latham & Watkins LLP advised on the acquisition of Simulations Plus, Inc. by affiliates of Altaris, LLC for approximately US$375 million in an all-cash transaction. Simulations Plus, a leader in AI-accelerated drug development, is expected to be combined with Chemical Computing Group, an existing Altaris portfolio company. Latham & Watkins represented Truist Securities, Inc. as financial advisor to Altaris, with a team handling capital markets, tax, and UK finance matters.
Altaris to Take Simulations Plus Private in Acquisition
Altaris, LLC has agreed to acquire Simulations Plus (SLP) in an all-cash deal valued at approximately $375 million, with shareholders receiving $18.50 per share, representing a 26% premium. The acquisition, expected to close in Q4 2026, will combine Simulations Plus with Altaris's portfolio company Chemical Computing Group, taking Simulations Plus private and aiming to create a larger AI-driven drug development software platform. The deal is seen as a strategic move to address the life sciences industry's shift towards integrated, cloud-based, AI-driven platforms and subscription revenue models.
Simulations Plus to Be Acquired by Altaris for ~$375M; $18.50/Share Cash Offer
Simulations Plus has agreed to be acquired by Altaris affiliates for approximately $375 million, with stockholders receiving $18.50 per share in cash, a 26% premium to the 60-day VWAP as of June 15, 2026. The transaction is expected to close in Q4 2026 and will result in Simulations Plus becoming a private subsidiary combined with Chemical Computing Group. Simulations Plus will report its Q3 fiscal 2026 results on July 9, 2026, but will not be holding earnings calls during the pending transaction.
Simulations Plus to Be Acquired by Altaris For Approximately $375 Million
Simulations Plus, a leader in AI-accelerated drug development, announced it will be acquired by Altaris for approximately $375 million in an all-cash transaction. Stockholders will receive $18.50 per share, representing a 26% premium. Following the acquisition, Simulations Plus is expected to combine with Chemical Computing Group, an existing Altaris portfolio company, to strengthen its position in the life sciences industry.
SLP: Affiliate exercises 3,150 shares; director 10b5-1 sold 1,000 (SLP)
A recent Form 144 filing by Simulations Plus, Inc. (SLP) disclosed that an affiliate exercised options for 3,150 shares on June 15, 2026, and also reported a prior 10b5-1 sale of 1,000 shares on May 11, 2026, valued at $16,530.00. These transactions are routine affiliate disclosures. The filing provides key financial metrics related to these insider activities.
Securities Investigation Into Simulations Plus, Inc. (SLP)
Johnson Fistel, PLLP is investigating potential securities law violations concerning Simulations Plus, Inc. (NASDAQ: SLP) following significant stock declines and revised financial guidance. The investigation focuses on whether the company made false or misleading statements regarding its financial outlook, reporting practices, internal controls, and accounting after it reduced full-year revenue guidance and disclosed a large impairment charge and the dismissal of its auditor. Investors who suffered losses are encouraged to join the investigation.
Securities Investigation Into Simulations Plus, Inc. (SLP)
Johnson Fistel, PLLP is investigating potential securities law violations by Simulations Plus, Inc. (NASDAQ: SLP) following significant stock declines and financial disclosures. The investigation stems from a reduced revenue guidance, a substantial net loss including an impairment charge, and the dismissal of their independent accounting firm over unresolved matters related to financial reporting and internal controls. Investors who suffered losses are encouraged to contact Johnson Fistel to explore their legal rights.
Securities Investigation Into Simulations Plus, Inc. (SLP)
Johnson Fistel, PLLP is investigating potential securities law violations by Simulations Plus, Inc. (NASDAQ: SLP) following significant stock declines and financial disclosures. The investigation focuses on whether the company made false or misleading statements regarding its financial outlook and internal controls. Investors who suffered losses after purchasing Simulations Plus securities are encouraged to contact Johnson Fistel to explore their legal rights.
Simulations Plus (SLP) Securities Investigation: Johnson Fistel
Johnson Fistel, PLLP is investigating potential securities law violations concerning Simulations Plus, Inc. (NASDAQ: SLP) following significant drops in its stock price. The investigation focuses on whether the company or its officers made false or misleading statements regarding its financial outlook, reporting practices, internal controls, and accounting matters, which led to a revenue guidance cut, a $77.2 million impairment charge, and a dispute with its former auditor. Investors who suffered losses after purchasing Simulations Plus securities are encouraged to join the investigation.
Simulations Plus (SLP) Securities Investigation: Johnson Fistel Reviews Revenue Guidance Cut, $77.2M Impairment Charge, and Auditor Dispute
Johnson Fistel, PLLP is investigating Simulations Plus (SLP) for potential securities law violations after the company cut its fiscal 2025 revenue guidance, reported a $77.2 million impairment charge, and dismissed its auditor, Grant Thornton LLP. These events led to significant drops in stock price, with Grant Thornton disagreeing with aspects of Simulations Plus's disclosure concerning internal control issues. Investors who purchased SLP securities and suffered losses are encouraged to join the investigation.
Simulations Plus (SLP) Securities Investigation: Johnson Fistel Reviews Revenue Guidance Cut, $77.2M Impairment Charge, and Auditor Dispute
Johnson Fistel, PLLP is investigating potential securities law violations by Simulations Plus, Inc. (NASDAQ: SLP) following significant financial disclosures. The investigation focuses on a reduced revenue guidance, a $77.2 million non-cash impairment charge, and a dispute with its former auditor, Grant Thornton LLP, regarding internal controls and reporting practices. Investors who suffered losses after purchasing Simulations Plus securities are encouraged to join the investigation.
Robbins LLP Reminds SLP Stockholders of its Investigation into Simulation Plus, Inc.; Contact the Firm for Information
Robbins LLP is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine if its officers and directors violated securities laws. This follows significant stock drops after the company announced disappointing fiscal 2025 results, updated revenue outlook, and dismissed its auditor, citing issues with segment reporting and internal controls. Shareholders who lost money are encouraged to contact Robbins LLP for information regarding their rights.
Simulations Plus (SLP) Securities Investigation: Johnson Fistel Reviews Revenue Guidance Cut, $77.2M Impairment Charge, and Auditor Dispute
Johnson Fistel, PLLP is investigating Simulations Plus (SLP) for potential securities law violations after the company cut its full-year 2025 revenue guidance, disclosed a $77.2 million impairment charge, and had a public dispute with its former auditor, Grant Thornton LLP. These events led to significant drops in Simulations Plus's stock price. Investors who suffered losses are encouraged to join the investigation.
Insider Sell: DiBella John Anthony II Sells Shares of Simulations Plus Inc (SLP)
John Anthony II DiBella, Chief Revenue Officer of Cognigen Corporation (a subsidiary of Simulations Plus Inc), sold 1,000 shares of Simulations Plus Inc (SLP) on June 3, 2026. This sale expands his total sales over the past year to 3,000 shares, with no purchases. Simulations Plus Inc's stock was trading at $16.50, significantly below its GF Value of $38.24, indicating it is undervalued.
Simulations Plus (SLP) CRO auto-sells 1,000 shares under Rule 10b5-1 plan
Simulations Plus (SLP) Chief Revenue Officer, John Anthony DiBella II, automatically sold 1,000 shares of company stock at $16.50 per share under a pre-arranged Rule 10b5-1 trading plan. This transaction represents a small fraction of his holdings, as he still directly owns 87,140 shares after the sale. The sale was disclosed in a Form 4 filing, which provides transparency on insider transactions.
